Furthermore, HOXD-AS1 led to chemoresistance of prostate cancer cells (LNCaP and PC-3) to paclitaxel through activating the transcription of target genes directly by recruiting WDR5 to mediate histone H3 lysine 4 tri-methylation (H3K4me3) at their promoter region [21]. This evidence concerns the gene WDR5 and prostate carcinoma.